Breaking News Instant updates and real-time market news.

SPGI

S&P Global

$264.34

-3.6 (-1.34%)

, INFO

IHS Markit

$71.62

-0.38 (-0.53%)

18:06
11/21/19
11/21
18:06
11/21/19
18:06

Jefferies initiates Information Services sector

Jefferies analyst Hamzah Mazari initiated select names across the Information Services sector as part of his broader research note covering the Business Services industry. The analyst has a Buy rating on S&P Global (SPGI) with a $298 price target, Verisk (VRSK) with a $174 price target, and Equifax (EFX) with a $169 price target, citing their respective positives of potential multiple expansion from the growth of China Ratings, the benefits of investment cycle driving free cash flow investment, and faster organic growth supported by the technological transformation under the new management. The analyst also starts IHS Markit (INFO), Gartner (IT), FactSet (FDS), Transunion (TRU), and CoStar (CSGP) at Hold with respective $76, $178, $253, $86, and $601 price targets. Mazari warns about their respective exposure to energy market downside, greater focus on margins over growth, competitive cost pressures, high leverage, and valuation.

SPGI

S&P Global

$264.34

-3.6 (-1.34%)

INFO

IHS Markit

$71.62

-0.38 (-0.53%)

VRSK

Verisk Analytics

$144.45

0.12 (0.08%)

IT

Gartner

$158.00

0.06 (0.04%)

FDS

FactSet

$258.20

-3.65 (-1.39%)

EFX

Equifax

$137.97

-1.15 (-0.83%)

TRU

TransUnion

$84.90

-1.34 (-1.55%)

CSGP

CoStar Group

$587.66

-7.45 (-1.25%)

  • 02

    Dec

  • 19

    Dec

  • 19

    Dec

  • 07

    Jan

SPGI S&P Global
$264.34

-3.6 (-1.34%)

10/30/19
BMOC
10/30/19
NO CHANGE
Target $266
BMOC
Market Perform
S&P Global price target raised to $266 from $255 at BMO Capital
BMO Capital analyst Jeffrey Silber raised his price target on S&P Global to $266 after its Q3 earnings beat driven by better than expected revenues and margins. The analyst notes that the company's organic growth accelerated amid a rebound in high-yield and investment-grade bond issuance as well as "broad-based" index inflows. With growth forecasts seen as "steady" across a number of S&P's data and analytics businesses, Silber believes that the outlook for the company is "solid", but also keeps his Market Perform rating citing valuation.
11/01/19
11/01/19
NO CHANGE

Rice University-Jones Graduate School of Business to hold a summit
Rice Energy Finance Summit will be held in Houston on November 1.
08/06/19
ATLE
08/06/19
DOWNGRADE
ATLE
Neutral
S&P Global downgraded to Neutral from Overweight at Atlantic Equities
11/21/19
JEFF
11/21/19
INITIATION
Target $298
JEFF
Buy
S&P Global initiated with a Buy at Jefferies
Jefferies analyst Hamzah Mazari initiated coverage of S&P Global with a Buy rating and $298 price target.
INFO IHS Markit
$71.62

-0.38 (-0.53%)

11/13/19
RHCO
11/13/19
NO CHANGE
Target $80
RHCO
Buy
IHS Markit price target raised to $80 from $74 at SunTrust
SunTrust analyst Andrew Jeffrey raised his price target on IHS Markit to $80 and kept his Buy rating after its raised FY19 and initial FY20 guidance. The analyst notes that the sustainability of the company's organic revenue growth is becoming clearer, forecasting "consistent" mid-single digit gains along with above-industry average EBITDA margin expansion and strong free cash flows. Jeffrey contends that IHS Markit stock should continue re-rating toward the high end of the Info Services group.
11/13/19
CANT
11/13/19
NO CHANGE
Target $65
CANT
Neutral
IHS Markit price target raised to $65 from $59 at Cantor Fitzgerald
Cantor Fitzgerald analyst Joseph Foresi raised his price target for IHS Markit to $65 from $59 after the company updated its fiscal 2019 guidance and announced fiscal 2020 guidance. Revenue projections were lower than expected, but only due to a loss of $70M from the disposition of IHS's Aerospace & Defense segment, Foresi tells investors in a research note. He keeps a Neutral rating on the shares.
11/21/19
JEFF
11/21/19
INITIATION
Target $76
JEFF
Hold
IHS Markit initiated with a Hold at Jefferies
Jefferies analyst Hamzah Mazari initiated coverage of IHS Markit with a Hold rating and $76 price target.
VRSK Verisk Analytics
$144.45

0.12 (0.08%)

10/31/19
EVER
10/31/19
DOWNGRADE
Target $154
EVER
In Line
Verisk Analytics downgraded to In Line from Outperform at Evercore ISI
Evercore ISI analyst David Togut downgraded Verisk Analytics to In Line from Outperform with a $154 price target.
11/21/19
JEFF
11/21/19
INITIATION
Target $174
JEFF
Buy
Verisk Analytics initiated with a Buy at Jefferies
Jefferies analyst Hamzah Mazari initiated coverage of Verisk Analytics with a Buy rating and $174 price target.
09/23/19
09/23/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Verisk Analytics (VRSK) assumed with a Market Perform at Keefe Bruyette. 2. Easterly Government Properties (DEA) initiated with a Buy at Compass Point. 3. Elanco (ELAN) initiated with an Overweight at Barclays. 4. Accenture (ACN) initiated with a Buy at Redburn. 5. Lululemon (LULU) initiated with an Overweight at Piper Jaffray. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/22/19
KBWI
09/22/19
INITIATION
Target $166
KBWI
Market Perform
Verisk Analytics assumed with a Market Perform at Keefe Bruyette
Keefe Bruyette analyst Christopher Campbell assumed coverage of Verisk Analytics with a Market Perform rating and $166 price target. The analyst sees "modest" upside in the shares, driven by improving Energy growth, Insurance growth and "solid" free cash flow conversion, partly offset by slower Financial Services revenue growth.
IT Gartner
$158.00

0.06 (0.04%)

07/31/19
BMOC
07/31/19
NO CHANGE
Target $142
BMOC
Market Perform
Gartner price target lowered to $142 from $161 at BMO Capital
BMO Capital analyst Jeffrey Silber lowered his price target on Gartner to $142 and kept his Market Perform rating after its FY19 guidance cut driven by reduced Research revenue expectations that include lower "legacy" non-subscription revenues in global business sales, or GBS. The analyst also remains concerned by the stock's "high valuations" and the "ongoing" GBS transition issues.
05/08/19
CANT
05/08/19
NO CHANGE
Target $152
CANT
Neutral
Gartner price target raised to $152 from $141 at Cantor Fitzgerald
Cantor Fitzgerald analyst Joseph Foresi raised his price target for Gartner to $152 from $141 following the company's Q1 results but keeps a Neutral rating on the shares.
11/21/19
JEFF
11/21/19
INITIATION
Target $178
JEFF
Hold
Gartner initiated with a Hold at Jefferies
Jefferies analyst Hamzah Mazari initiated coverage of Gartner with a Hold rating and $178 price target.
02/06/19
CANT
02/06/19
DOWNGRADE
CANT
Neutral
Gartner downgraded to Neutral from Overweight at Cantor Fitzgerald
FDS FactSet
$258.20

-3.65 (-1.39%)

11/21/19
JEFF
11/21/19
INITIATION
Target $253
JEFF
Hold
FactSet initiated with a Hold at Jefferies
Jefferies analyst Hamzah Mazari initiated coverage of FactSet with a Hold rating and $253 price target.
09/27/19
CANT
09/27/19
NO CHANGE
Target $240
CANT
Neutral
FactSet price target lowered to $240 from $270 at Cantor Fitzgerald
Cantor Fitzgerald analyst Joseph Foresi lowered his price target for FactSet Research Systems to $240 from $270 after the company issued fiscal 2020 guidance below consensus. Management will be focused on building out its portfolio and accelerating growth over the long term, says the analyst, who maintains a Neutral rating on the shares.
09/27/19
MSCO
09/27/19
NO CHANGE
Target $217
MSCO
Underweight
FactSet price target lowered to $217 from $263 at Morgan Stanley
Morgan Stanley analyst Toni Kaplan said that FactSet's guidance for 0% adjusted EPS growth in FY20 represents a "marked deceleration" from prior years and was below her previous estimate for 6% growth. Adjusted operating margin guidance implies year-over-year margin contraction of 100 bps, compared to her previous expectation for 40 bps of expansion, added Kaplan, who thinks investments in content and technology over the next three years should limit future margin expansion through FY22. Kaplan keeps an Underweight rating on FactSet shares and cut her price target on the stock to $217 from $263, contending that the outlook for FY20 "shows limited reason to be excited over the next few years."
09/27/19
DADA
09/27/19
NO CHANGE
Target $240
DADA
Neutral
FactSet price target lowered to $240 from $252 at DA Davidson
DA Davidson analyst Peter Heckmann lowered his price target on FactSet to $240 and kept his Neutral rating to reflect the company's "notably" lower than expected 2020 guidance for margins and earnings. The analyst also lowers his FY20 EPS target by 5.5% to $10.02 and FY21 view by 8% to $10.60, with lower growth/margin rates next year and flattish levels for both the following year. Heckmann adds that the "aspirational growth goal" for FactSet's Annual Subscription Value set by its management represents a "fairly high bar".
EFX Equifax
$137.97

-1.15 (-0.83%)

10/25/19
FBCO
10/25/19
NO CHANGE
Target $157
FBCO
Outperform
Equifax price target raised to $157 from $150 at Credit Suisse
Credit Suisse analyst Kevin McVeigh raised his price target for Equifax to $157 from $150 and maintained an Outperform rating, saying he would conintue to strategically accumulate the stock on weakness as its Q3 and Q4 outlook reinforces his view that the cyber incident has had no meaningful structural fundamental impact, as revenue trends continue to improve.
07/30/19
ATLE
07/30/19
DOWNGRADE
ATLE
Neutral
TransUnion downgraded to Neutral from Overweight at Atlantic Equities
Atlantic Equities analyst Kunaal Malde downgraded TransUnion (TRU) to Neutral from Overweight saying he prefers shares of Equifax (EFX) at current levels.
07/26/19
RHCO
07/26/19
NO CHANGE
Target $155
RHCO
Buy
Equifax price target raised to $155 from $130 at SunTrust
SunTrust analyst Andrew Jeffrey raised his price target on Equifax to $155 and kept his Buy rating after its Q2 earnings beat. The analyst notes that while the soft Q3 outlook has weighed on the stock price after-hours, the weakness is creating an attractive entry point given the "apparent recovery in US Information Solutions sales momentum", "continued robust" Equifax Workforce Solutions segment performance, and a better margin outlook.
11/21/19
JEFF
11/21/19
INITIATION
Target $169
JEFF
Buy
Equifax initiated with a Buy at Jefferies
Jefferies analyst Hamzah Mazari initiated coverage of Equifax with a Buy rating and $169 price target.
TRU TransUnion
$84.90

-1.34 (-1.55%)

04/24/19
BARD
04/24/19
NO CHANGE
Target $78
BARD
Outperform
TransUnion still a top idea despite 'modestly disappointing' Q1, says Baird
Baird analyst Jeffrey Meuler said TransUnion's Q1 results were "modestly disappointing, but not thesis changing" and the stock remains his top information solutions idea given that he expects accelerating growth in the near-term and sustained strong growth at attractive economics over the long-term. Despite the Q1 results, strong bookings trends, improved trends in shorter-cycle/batch revenue in March/April relative to January/February and a more favorable mortgage market outlook are among the factors he points to that give him confidence in a reacceleration. Meuler keeps an Outperform rating on TransUnion shares and raised his price target on the stock to $78 from $75.
07/24/19
RHCO
07/24/19
NO CHANGE
Target $90
RHCO
Buy
TransUnion price target raised to $90 from $78 at SunTrust
SunTrust analyst Andrew Jeffrey raised his price target on TransUnion to $90 and kept his Buy rating after its Q2 earnings beat and raised FY19 guidance, saying that while its valuation is "pushing the limit", he believes that company can expand its margins and grow its organic revenue by over 6%. Jeffrey also maintains his positive view on the company's position in Insurance and is also enthused by its "apparent re-acceleration" in emerging verticals like Healthcare.
11/21/19
JEFF
11/21/19
INITIATION
Target $86
JEFF
Hold
TransUnion initiated with a Hold at Jefferies
Jefferies analyst Hamzah Mazari initiated coverage of TransUnion with a Hold rating and $86 price target.
CSGP CoStar Group
$587.66

-7.45 (-1.25%)

10/23/19
NEED
10/23/19
NO CHANGE
Target $600
NEED
Buy
CoStar Group price target lowered to $600 from $675 at Needham
Needham analyst Mayank Tandon lowered his price target on CoStar Group to $600, saying that while its Q3 earnings topped consensus, the company cut its FY19 outlook as its multifamily investments are expected to weigh on its margins over the near term. The analyst adds that CoStar's acquisition integration costs and the $100M marketing investment spend to boost its market share are expected to pressure its EBITDA margins by about 400bps in FY20. Tandon is keeping his Buy rating but lowering his FY19 and FY20 EPS view by 12c and $1.65 to $10.00 and $10.20 to reflect the reduced EBITDA margins.
10/21/19
RILY
10/21/19
NO CHANGE
Target $640
RILY
Buy
CoStar Group price target raised to $640 from $610 at B. Riley FBR
B. Riley FBR analyst Scott Buck raised his price target for CoStar Group to $640 from $610 and maintains a Buy rating on the shares ahead of the company's Q3 results on October 22. While the analyst expects the quarter to be largely in line, he believes the announced STR acquisition will allow the company to continue to grow revenue at an industry-leading rate for an additional two or three years.
07/24/19
RHCO
07/24/19
NO CHANGE
Target $650
RHCO
Buy
CoStar Group price target raised to $650 from $560 at SunTrust
SunTrust analyst Andrew Jeffrey raised his price target on CoStar Group to $650 and kept his Buy rating, saying the record bookings recorded by the company in Q2 reflect its sales force growth. The analyst contends that the company should be able to sustain its mid-teen organic revenue growth as it builds on the leadership in its commercial real estate platform and benefits from "impressive" multi-family sales.
11/21/19
JEFF
11/21/19
INITIATION
Target $601
JEFF
Hold
CoStar Group initiated with a Hold at Jefferies
Jefferies analyst Hamzah Mazari initiated coverage of CoStar Group with a Hold rating and $601 price target.

TODAY'S FREE FLY STORIES

PLMR

Palomar

20:27
12/08/19
12/08
20:27
12/08/19
20:27
Recommendations
Palomar analyst commentary  »

Palomar price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

ASAZY

Assa Abloy

$0.00

(0.00%)

20:23
12/08/19
12/08
20:23
12/08/19
20:23
Downgrade
Assa Abloy rating change  »

Assa Abloy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RXEEY

Rexel

$0.00

(0.00%)

20:23
12/08/19
12/08
20:23
12/08/19
20:23
Upgrade
Rexel rating change  »

Rexel upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TATYY

Tate & Lyle

$0.00

(0.00%)

20:22
12/08/19
12/08
20:22
12/08/19
20:22
Upgrade
Tate & Lyle rating change  »

Tate & Lyle upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUO

AU Optronics

$0.00

(0.00%)

20:20
12/08/19
12/08
20:20
12/08/19
20:20
Upgrade
AU Optronics rating change  »

AU Optronics upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPL

LG Display

$6.22

0.115 (1.89%)

20:17
12/08/19
12/08
20:17
12/08/19
20:17
Upgrade
LG Display rating change  »

LG Display upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

ETNB

89bio

$28.38

0.86 (3.13%)

20:16
12/08/19
12/08
20:16
12/08/19
20:16
Initiation
89bio initiated  »

89bio initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANIOY

Acerinox

$0.00

(0.00%)

20:15
12/08/19
12/08
20:15
12/08/19
20:15
Upgrade
Acerinox rating change  »

Acerinox upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

20:15
12/08/19
12/08
20:15
12/08/19
20:15
Conference/Events
Blueprint Medicines to hold an anlayst and investor event »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

TLSNY

Telia

$0.00

(0.00%)

20:14
12/08/19
12/08
20:14
12/08/19
20:14
Downgrade
Telia rating change  »

Telia downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARWR

Arrowhead

$67.25

1.705 (2.60%)

20:13
12/08/19
12/08
20:13
12/08/19
20:13
Recommendations
Arrowhead analyst commentary  »

Arrowhead price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARGX

Argenx

$147.31

-2.56 (-1.71%)

20:08
12/08/19
12/08
20:08
12/08/19
20:08
Recommendations
Argenx analyst commentary  »

Argenx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

STC

Stewart

$43.16

0.28 (0.65%)

19:56
12/08/19
12/08
19:56
12/08/19
19:56
Downgrade
Stewart rating change  »

Stewart downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FAF

First American

$63.05

(0.00%)

19:55
12/08/19
12/08
19:55
12/08/19
19:55
Downgrade
First American rating change  »

First American downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

PFSI

PennyMac Financial

$33.91

0.12 (0.36%)

19:54
12/08/19
12/08
19:54
12/08/19
19:54
Downgrade
PennyMac Financial rating change  »

PennyMac downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

18:40
12/08/19
12/08
18:40
12/08/19
18:40
Recommendations
Agios Pharmaceuticals analyst commentary at Piper Jaffray »

Agios' initial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

18:34
12/08/19
12/08
18:34
12/08/19
18:34
Recommendations
Blueprint Medicines analyst commentary at Piper Jaffray »

Piper says 'jury…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

18:29
12/08/19
12/08
18:29
12/08/19
18:29
Recommendations
Fate Therapeutics analyst commentary at Piper Jaffray »

FT500 data validates Fate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCKT

Rocket Pharmaceuticals

$22.37

2.61 (13.21%)

18:05
12/08/19
12/08
18:05
12/08/19
18:05
Hot Stocks
Rocket says Phase 1 trial establishes feasibility of commercial Process B for FA »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

ARGX

Argenx

$147.31

-2.56 (-1.71%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

18:03
12/08/19
12/08
18:03
12/08/19
18:03
Recommendations
Argenx, Johnson & Johnson analyst commentary at Piper Jaffray »

Argenx data on…

ARGX

Argenx

$147.31

-2.56 (-1.71%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 16

    Dec

  • 21

    Jan

BLUE

Bluebird Bio

$79.51

-1.24 (-1.54%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

17:58
12/08/19
12/08
17:58
12/08/19
17:58
Recommendations
Bluebird Bio, Johnson & Johnson, Amgen, Bristol-Myers, Regeneron analyst commentary at Piper Jaffray »

Piper says…

BLUE

Bluebird Bio

$79.51

-1.24 (-1.54%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

AMGN

Amgen

$233.74

0.3 (0.13%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

REGN

Regeneron

$372.26

4.02 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

  • 21

    Jan

BGNE

BeiGene

$186.89

-2.3 (-1.22%)

17:50
12/08/19
12/08
17:50
12/08/19
17:50
Hot Stocks
BeiGene announces data from two clinical trials of Brukinsa at ASH meeting »

BeiGene announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 27

    Feb

LLY

Eli Lilly

$119.59

-0.175 (-0.15%)

16:34
12/08/19
12/08
16:34
12/08/19
16:34
Hot Stocks
Eli Lilly presents interim clinical data from LOXO-305 dose escalation trial »

Eli Lilly announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 17

    Dec

  • 30

    Jan

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

16:32
12/08/19
12/08
16:32
12/08/19
16:32
Hot Stocks
Bristol-Myers announces data from multiple liso-cel studies at ASH meeting »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

QURE

uniQure

$66.06

1.5 (2.32%)

16:26
12/08/19
12/08
16:26
12/08/19
16:26
Hot Stocks
uniQure reports 1-year follow-up data from etranacogene dezaparvovec study »

uniQure announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.